1
|
Raphael HE, Hassan GF, Osorio OA, Cohen LS, Payne MD, Katz-Kiriakos E, Tata I, Hicks J, Byers DE, Zhang B, Alexander-Brett J. Activator protein transcription factors coordinate human IL-33 expression from noncanonical promoters in chronic airway disease. JCI Insight 2024; 9:e174786. [PMID: 38456508 DOI: 10.1172/jci.insight.174786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 01/22/2024] [Indexed: 03/09/2024] Open
Abstract
IL-33 is a cytokine central to type 2 immune pathology in chronic airway disease. This cytokine is abundantly expressed in the respiratory epithelium and increased in disease, but how expression is regulated is undefined. Here we show that increased IL33 expression occurs from multiple noncanonical promoters in human chronic obstructive pulmonary disease (COPD), and it facilitates production of alternatively spliced isoforms in airway cells. We found that phorbol 12-myristate 13-acetate (PMA) can activate IL33 promoters through protein kinase C in primary airway cells and lines. Transcription factor (TF) binding arrays combined with RNA interference identified activator protein (AP) TFs as regulators of baseline and induced IL33 promoter activity. ATAC-Seq and ChIP-PCR identified chromatin accessibility and differential TF binding as additional control points for transcription from noncanonical promoters. In support of a role for these TFs in COPD pathogenesis, we found that AP-2 (TFAP2A, TFAP2C) and AP-1 (FOS and JUN) family members are upregulated in human COPD specimens. This study implicates integrative and pioneer TFs in regulating IL33 promoters and alternative splicing in human airway basal cells. Our work reveals a potentially novel approach for targeting IL-33 in development of therapeutics for COPD.
Collapse
Affiliation(s)
- Heather E Raphael
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Ghandi F Hassan
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Omar A Osorio
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Lucy S Cohen
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Morgan D Payne
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Ella Katz-Kiriakos
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Ishana Tata
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Jamie Hicks
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Derek E Byers
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
| | - Bo Zhang
- Department of Developmental Biology, and
| | - Jen Alexander-Brett
- Department of Medicine, Division of Pulmonary and Critical Care Medicine
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
| |
Collapse
|
2
|
Katz-Kiriakos E, Steinberg DF, Kluender CE, Osorio OA, Newsom-Stewart C, Baronia A, Byers DE, Holtzman MJ, Katafiasz D, Bailey KL, Brody SL, Miller MJ, Alexander-Brett J. Epithelial IL-33 appropriates exosome trafficking for secretion in chronic airway disease. JCI Insight 2021; 6:136166. [PMID: 33507882 PMCID: PMC7934940 DOI: 10.1172/jci.insight.136166] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Accepted: 01/15/2021] [Indexed: 02/06/2023] Open
Abstract
IL-33 is a key mediator of chronic airway disease driven by type 2 immune pathways, yet the nonclassical secretory mechanism for this cytokine remains undefined. We performed a comprehensive analysis in human airway epithelial cells, which revealed that tonic IL-33 secretion is dependent on the ceramide biosynthetic enzyme neutral sphingomyelinase 2 (nSMase2). IL-33 is cosecreted with exosomes by the nSMase2-regulated multivesicular endosome (MVE) pathway as surface-bound cargo. In support of these findings, human chronic obstructive pulmonary disease (COPD) specimens exhibited increased epithelial expression of the abundantly secreted IL33Δ34 isoform and augmented nSMase2 expression compared with non-COPD specimens. Using an Alternaria-induced airway disease model, we found that the nSMase2 inhibitor GW4869 abrogated both IL-33 and exosome secretion as well as downstream inflammatory pathways. This work elucidates a potentially novel aspect of IL-33 biology that may be targeted for therapeutic benefit in chronic airway diseases driven by type 2 inflammation.
Collapse
Affiliation(s)
- Ella Katz-Kiriakos
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and
| | - Deborah F Steinberg
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and
| | - Colin E Kluender
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and
| | - Omar A Osorio
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and
| | | | - Arjun Baronia
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and
| | - Derek E Byers
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and
| | - Michael J Holtzman
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and.,Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Dawn Katafiasz
- Department of Medicine, Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Kristina L Bailey
- Department of Medicine, Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Steven L Brody
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and
| | - Mark J Miller
- Department of Medicine, Division of Infectious Diseases, and
| | - Jennifer Alexander-Brett
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, and.,Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
| |
Collapse
|